26
Participants
Start Date
February 28, 2005
Primary Completion Date
January 31, 2011
Study Completion Date
January 31, 2011
111-In-DOTA-cG250
On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
177-Lu-DOTA-cG250
On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m\^2 in the initial cohort.
University Medical Center Nijmegen, Nijmegen
Lead Sponsor
Radboud University Medical Center
OTHER
Ludwig Institute for Cancer Research
OTHER